Published in Neurosci Lett on July 10, 2008
LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell (2011) 3.78
Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta (2008) 1.55
A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol Cell Proteomics (2010) 1.15
Regulation of LRRK2 stability by the E3 ubiquitin ligase CHIP. PLoS One (2009) 1.07
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 1.05
LRRK2 function on actin and microtubule dynamics in Parkinson disease. Commun Integr Biol (2010) 1.04
Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders. J Neurosci (2014) 0.99
Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS One (2013) 0.93
Genetic factors and manganese-induced neurotoxicity. Front Genet (2014) 0.90
The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. Antioxid Redox Signal (2009) 0.90
LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol (2014) 0.88
The use of neuroproteomics in drug abuse research. Drug Alcohol Depend (2009) 0.77
Parkinson's disease: leucine-rich repeat kinase 2 and autophagy, intimate enemies. Parkinsons Dis (2012) 0.75
Differentiation and Characterization of Dopaminergic Neurons From Baboon Induced Pluripotent Stem Cells. Stem Cells Transl Med (2016) 0.75
The FOXP2-Driven Network in Developmental Disorders and Neurodegeneration. Front Cell Neurosci (2017) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med (2006) 3.90
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med (2006) 2.93
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience (2007) 1.86
Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem (2006) 1.85
Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet (2007) 1.72
Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet (2007) 1.65
Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci (2007) 1.59
LRRK2 expression linked to dopamine-innervated areas. Ann Neurol (2006) 1.54
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res (2007) 1.50
Genetics of parkinsonism. Mov Disord (2002) 1.38
Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends Neurosci (2005) 1.32
Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience (2006) 1.28
Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol (2005) 1.18
Parkinson's disease: a genetic perspective. FEBS J (2008) 1.16
The human tyrosine hydroxylase gene promoter. Brain Res Mol Brain Res (2003) 1.04
LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur J Neurosci (2006) 1.02
Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol (2006) 0.97
Purified mouse dopamine neurons thrive and function after transplantation into brain but require novel glial factors for survival in culture. Mol Cell Neurosci (2005) 0.86
Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell (2009) 10.52
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol (2010) 7.62
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A (2002) 4.20
Human zinc fingers as building blocks in the construction of artificial transcription factors. Nat Biotechnol (2003) 4.03
Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells (2010) 3.48
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Mitochondrial genome variation in eastern Asia and the peopling of Japan. Genome Res (2004) 3.34
Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J Biol Chem (2005) 3.33
Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol (2008) 2.95
p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes Cells (2010) 2.91
PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy. Sci Rep (2012) 2.60
Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem (2005) 2.60
PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun (2012) 2.55
A vector-free microfluidic platform for intracellular delivery. Proc Natl Acad Sci U S A (2013) 2.40
Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest (2011) 2.23
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain (2012) 2.18
LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res (2008) 2.09
Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron (2007) 2.08
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet (2004) 2.02
Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet (2012) 2.01
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep (2003) 2.01
Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol (2009) 2.00
Gradient echo T2*-weighted magnetic resonance imaging revealing cerebral microbleeds in a patient with microscopic polyangiitis complicated by cerebrovascular disease. J Stroke Cerebrovasc Dis (2011) 1.99
Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun (2009) 1.89
In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem (2005) 1.86
Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet (2006) 1.83
Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy (2011) 1.81
PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy. FEBS Lett (2010) 1.79
A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment-refractory auditory hallucinations. Neurosci Lett (2004) 1.79
Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther (2007) 1.76
Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur J Neurosci (2002) 1.75
Novel PINK1 mutations in early-onset parkinsonism. Ann Neurol (2004) 1.72
Essential role for TRPC5 in amygdala function and fear-related behavior. Cell (2009) 1.72
Mechanism and treatment of dropped head syndrome associated with parkinsonism. Parkinsonism Relat Disord (2008) 1.68
Fabrication, characterization, and application of boron-doped diamond microelectrodes for in vivo dopamine detection. Anal Chem (2007) 1.67
Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. Stem Cells (2002) 1.67
Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol (2006) 1.66
Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res (2003) 1.66
Phenotypic alteration of eukaryotic cells using randomized libraries of artificial transcription factors. Nat Biotechnol (2003) 1.65
Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet (2007) 1.65
A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem (2005) 1.60
Reversible cerebral vasoconstriction syndrome presenting as subarachnoid hemorrhage, reversible posterior leukoencephalopathy, and cerebral infarction. Intern Med (2011) 1.55
UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol (2004) 1.54
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease. J Neurosci (2005) 1.52
Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell (2009) 1.51
MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell (2010) 1.49
The apolipoprotein E epsilon4 haplotype is an important predictor for recurrence in ischemic cerebrovascular disease. J Neurol Sci (2003) 1.49
Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem (2006) 1.46
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab (2011) 1.40
Siah-1 facilitates ubiquitination and degradation of synphilin-1. J Biol Chem (2003) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. Mol Cell Neurosci (2005) 1.29
Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem (2009) 1.27
A rotarod test for evaluation of motor skill learning. J Neurosci Methods (2010) 1.26
Effect of wild-type or mutant Parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem (2002) 1.25
Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J Biol Chem (2005) 1.25
Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord (2009) 1.25
Ubiquitin, proteasome and parkin. Biochim Biophys Acta (2004) 1.25
Anxiogenic-like effect of chronic corticosterone in the light-dark emergence task in mice. Behav Neurosci (2006) 1.24
A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A (2006) 1.23
Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport (2007) 1.23
Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. J Neurochem (2007) 1.22
Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc Natl Acad Sci U S A (2013) 1.22
Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem Cells (2005) 1.22
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
LRRK2 enhances oxidative stress-induced neurotoxicity via its kinase activity. Exp Cell Res (2009) 1.21
Molecular consequences of PHOX2B missense, frameshift and alanine expansion mutations leading to autonomic dysfunction. Hum Mol Genet (2005) 1.20
Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord (2006) 1.20
14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J (2005) 1.18
Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation. Eur J Neurosci (2004) 1.18
The role of Lmx1a in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson's disease model. Stem Cells (2009) 1.17
ES cell-derived renewable and functional midbrain dopaminergic progenitors. Proc Natl Acad Sci U S A (2011) 1.17
Changes in host blood factors and brain glia accompanying the functional recovery after systemic administration of bone marrow stem cells in ischemic stroke rats. Cell Transplant (2010) 1.15
Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev (2010) 1.15
Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat. Exp Neurol (2002) 1.15
Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum Genet (2008) 1.14
Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol Dis (2010) 1.14
PEST motif sequence regulating human NANOG for proteasomal degradation. Stem Cells Dev (2011) 1.11
Custom DNA-binding proteins and artificial transcription factors. Curr Top Med Chem (2003) 1.11
Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet (2002) 1.11
Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet (2010) 1.10
Studies on the differentiation of dopaminergic traits in human neural progenitor cells in vitro and in vivo. Cell Transplant (2004) 1.10
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol (2006) 1.09
Circumventricular organs: a novel site of neural stem cells in the adult brain. Mol Cell Neurosci (2009) 1.08
Characterization of five evolutionary conserved regions of the human tyrosine hydroxylase (TH) promoter: implications for the engineering of a human TH minimal promoter assembled in a self-inactivating lentiviral vector system. J Cell Physiol (2005) 1.08
Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet (2003) 1.07
Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry (2011) 1.07
Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord (2006) 1.06
Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol (2009) 1.06
Fibroblast growth factor 20 gene and Parkinson's disease in the Japanese population. Neuroreport (2007) 1.05